Free Trial
NASDAQ:ENLV

Enlivex Therapeutics (ENLV) Stock Price, News & Analysis

$1.38
-0.02 (-1.43%)
(As of 05/28/2024 ET)
Today's Range
$1.31
$1.50
50-Day Range
$1.27
$4.31
52-Week Range
$1.15
$4.59
Volume
266,281 shs
Average Volume
145,724 shs
Market Capitalization
$25.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Enlivex Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
422.4% Upside
$7.00 Price Target
Short Interest
Healthy
1.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.99mentions of Enlivex Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.86) to ($0.55) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.32 out of 5 stars

Medical Sector

307th out of 931 stocks

Pharmaceutical Preparations Industry

142nd out of 433 stocks

ENLV stock logo

About Enlivex Therapeutics Stock (NASDAQ:ENLV)

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

ENLV Stock Price History

ENLV Stock News Headlines

ENLV Apr 2024 7.500 call
Enlivex Therapeutics Ltd.
ENLV May 2024 5.000 put
See More Headlines
Receive ENLV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/29/2024
Today
5/28/2024
Next Earnings (Estimated)
6/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ENLV
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+422.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-29,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.62 per share

Miscellaneous

Free Float
16,315,000
Market Cap
$24.92 million
Optionable
Optionable
Beta
1.22
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Shai Novik M.B.A. (Age 58)
    Executive Chairman
    Comp: $528k
  • Dr. Oren Hershkovitz Ph.D. (Age 47)
    Chief Executive Officer
    Comp: $273.6k
  • Prof. Dror Mevorach M.D. (Age 68)
    Founder and Chief Scientific & Medical Officer
    Comp: $180k
  • Ms. Shachar Shlosberger CPA (Age 47)
    Chief Financial Officer
    Comp: $126k
  • Mr. Veronique Amor-Baroukh
    Senior Director of Operations
  • Ms. Sigal Arad
    Director of HR

ENLV Stock Analysis - Frequently Asked Questions

Should I buy or sell Enlivex Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enlivex Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ENLV shares.
View ENLV analyst ratings
or view top-rated stocks.

What is Enlivex Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued 12-month price objectives for Enlivex Therapeutics' stock. Their ENLV share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next year. This suggests a possible upside of 422.4% from the stock's current price.
View analysts price targets for ENLV
or view top-rated stocks among Wall Street analysts.

How have ENLV shares performed in 2024?

Enlivex Therapeutics' stock was trading at $2.70 at the beginning of 2024. Since then, ENLV stock has decreased by 50.4% and is now trading at $1.34.
View the best growth stocks for 2024 here
.

Are investors shorting Enlivex Therapeutics?

Enlivex Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 230,600 shares, a decline of 12.4% from the April 30th total of 263,200 shares. Based on an average trading volume of 173,600 shares, the short-interest ratio is currently 1.3 days.
View Enlivex Therapeutics' Short Interest
.

When is Enlivex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, June 21st 2024.
View our ENLV earnings forecast
.

How were Enlivex Therapeutics' earnings last quarter?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) released its quarterly earnings data on Friday, March, 29th. The company reported ($0.48) EPS for the quarter.

What other stocks do shareholders of Enlivex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enlivex Therapeutics investors own include VBI Vaccines (VBIV), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Fulcrum Therapeutics (FULC), Soleno Therapeutics (SLNO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

How do I buy shares of Enlivex Therapeutics?

Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ENLV) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners